Birchview Capital, LP Acadia Pharmaceuticals Inc Transaction History

Birchview Capital, LP

$108 Million
Q3 2024

A detailed history of Birchview Capital, LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Birchview Capital, LP holds 400,400 shares of ACAD stock, worth $6.68 Million. This represents 5.68% of its overall portfolio holdings.

Number of Shares

400,400

Previous 250,400 59.9%

Holding current value

$6.68 Million

Previous $4.07 Million 51.44%

% of portfolio

5.68%

Previous 4.07%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.14 - $19.14 $2.27 Million - $2.87 Million	150,000 Added 59.9%	400,400 $6.16 Million
Q1 2024 May 14, 2024	BUY	$17.79 - $30.86 $177,900 - $308,600	10,000 Added 4.16%	250,400 $4.63 Million
Q3 2023 Nov 14, 2023	SELL	$20.84 - $33.47 $187,560 - $301,230	-9,000 Reduced 3.61%	240,400 $5.01 Million
Q2 2022 Aug 12, 2022	BUY	$13.01 - $27.22 $650,500 - $1.36 Million	50,000 Added 25.08%	249,400 $3.51 Million
Q2 2021 Aug 10, 2021	BUY	$19.4 - $27.42 $434,559 - $614,208	22,400 Added 12.66%	199,400 $4.86 Million
Q1 2021 May 14, 2021	BUY	$25.02 - $54.99 $1.88 Million - $4.12 Million	75,000 Added 73.53%	177,000 $4.57 Million
Q3 2020 Nov 12, 2020	BUY	$36.42 - $57.0 $327,780 - $513,000	9,000 Added 9.68%	102,000 $4.21 Million
Q2 2020 Aug 10, 2020	BUY	$39.26 - $52.73 $39,260 - $52,730	1,000 Added 1.09%	93,000 $4.51 Million
Q1 2020 May 12, 2020	BUY	$31.65 - $46.87 $2.47 Million - $3.66 Million	78,000 Added 557.14%	92,000 $3.89 Million
Q3 2019 Nov 12, 2019	BUY	$22.22 - $44.01 $88,880 - $176,040	4,000 Added 40.0%	14,000 $504,000
Q2 2019 Aug 06, 2019	BUY	$23.32 - $28.12 $233,200 - $281,200	10,000 New	10,000 $267,000

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.7B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.

Account

Birchview Capital, LP Acadia Pharmaceuticals Inc Transaction History